FDAnews
www.fdanews.com/articles/120435-merck-says-investigational-cat-k-inhibitor-shows-positive-results

Merck Says Investigational Cat K Inhibitor Shows Positive Results

September 14, 2009
New data from a Phase IIB clinical study of odanacatib, Merck & Co., Inc.’s oral, once-weekly investigational treatment for osteoporosis, showed that when stopping treatment after two years, the increases in lower back bone mineral density were reversed over the next year, while BMD at the hip remained above levels observed at the start of the study.
Forbes